Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Diabetes, Obesity and Metabolism - Aims Obesity and diabetes have been identified as comorbidities frequently associated with severe forms of COVID‐19. Here, we specifically assessed the relationship between BMI...

SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes

posted 1 month

Mashup Score: 1

Diabetes, Obesity and Metabolism - Aim Almost all clinical practice guidelines recommend that SGLT2 inhibitors are used as second‐line pharmacotherapy in people with type 2 diabetes and chronic kidney...

SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes

posted 1 month

Mashup Score: 1

Diabetes, Obesity and Metabolism - Aim Almost all clinical practice guidelines recommend that SGLT2 inhibitors are used as second‐line pharmacotherapy in people with type 2 diabetes and chronic kidney...

  • Almost all guidelines recommend SGLT2i as 2nd line in T2DM & CKD/HF if not achieving glucose control on metformin But should “metformin 1st for all” be revisited given the latest trial evidence? A thread on metformin, guidelines & our new meta-analysis https://t.co/TWWw39RbfW

SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes

posted 1 month

Diabetes, Obesity and Metabolism - Aim Almost all clinical practice guidelines recommend that SGLT2 inhibitors are used as second‐line pharmacotherapy in people with type 2 diabetes and chronic kidney...

SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes

posted 1 month

Diabetes, Obesity and Metabolism - Aim Almost all clinical practice guidelines recommend that SGLT2 inhibitors are used as second‐line pharmacotherapy in people with type 2 diabetes and chronic kidney...

SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes

posted 1 month

Diabetes, Obesity and Metabolism - Aim Almost all clinical practice guidelines recommend that SGLT2 inhibitors are used as second‐line pharmacotherapy in people with type 2 diabetes and chronic kidney...

SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes

posted 1 month

Diabetes, Obesity and Metabolism - Aim Almost all clinical practice guidelines recommend that SGLT2 inhibitors are used as second‐line pharmacotherapy in people with type 2 diabetes and chronic kidney...

  • So what is the evidence for the effect of SGLT2 inhibitors, with and without metformin, on CV, renal and mortality outcomes? We pooled data from the CVOTs, CREDENCE and DAPA-HF in this meta-analysis https://t.co/TWWw39RbfW